Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium

By The Science Advisory Board staff writers

June 8, 2021 -- Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry. Its first initiative is to unite companies and organizations from multiple industries to develop cell and gene therapy specific process analytical technologies.

These technologies will enable monitoring and control during the manufacturing process, including improving batch yields and lowering manufacturing costs. Consortium members will collaborate and share research findings to integrate and combine cell and gene therapy PAT into their respective offerings.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.